Form D · Other

Trio Pharmaceuticals, Inc.

San Diego, CA · CIK 0001953931

Offering snapshot reported Dec 13, 2022 · SEC filing

Reported sold
$1.91M
Offering amount: $2.4M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 1, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$956K$1.91MNov 10, 2022: $1,531,883.00Nov 10, 2022Dec 13, 2022: $1,911,392.00Dec 13, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,531,883 → $1,911,392
  • Reported investors6 → 9

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 13, 2022Amendment$1,911,392$379,509vs Nov 10, 20229SEC filing
Nov 10, 2022Initial$1,531,883No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-464453

Source: Form D, filed Dec 13, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Shivarupam Bhowmik Director, Executive
Jeffrey Friedman Director
Reiner Laus Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
11956 Bernardo Plaza Drive, Suite 160
San Diego, CA, 92128